Melanoma Diagnostics
Using real-world data from NCI's SEER registry, researchers found that patients who got Castle's DecisionDx-Melanoma test had better survival outcomes than untested patients.
DermTech to Cut 15 Percent of Workforce in Restructuring to Focus on Skin Cancer Test
The San Diego-based company said it will halt its pipeline programs in order to focus on growing volume and reimbursement for its noninvasive melanoma DNA test.
Microbiotica Advancing Bacterial Signature to Improve Immunotherapy Response, Patient Selection
Premium
The firm is developing an oral capsule of live bacteria to improve response rates to checkpoint inhibitors and advancing a predictive test relying on the same bacterial signature.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.